# EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

> **NCT04892472** · PHASE2 · TERMINATED · sponsor: **NovoCure GmbH** · enrollment: 15 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DEVICE:** NovoTTF-200T
- **DRUG:** Pembrolizumab (MK-3475) 200 mg

## Key facts

- **NCT ID:** NCT04892472
- **Lead sponsor:** NovoCure GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-12
- **Primary completion:** 2025-01-10
- **Final completion:** 2025-01-10
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Phase 2 study terminated due to insufficient enrollment and was not based on safety concerns. Novocure is enrolling a new Phase 3 study of TTFields as a first line treatment for advanced/metastatic NSCLC (NCT06216301).
- **Last updated:** 2025-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04892472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04892472, "EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04892472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*